<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335171">
  <stage>Registered</stage>
  <submitdate>15/02/2010</submitdate>
  <approvaldate>18/02/2010</approvaldate>
  <actrnumber>ACTRN12610000161022</actrnumber>
  <trial_identification>
    <studytitle>Adrenergic control of protein and fat metabolism in healthy adults</studytitle>
    <scientifictitle>Impact of beta2-adrenergic stimulation on protein and fat metabolism in healthy adults</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Normal metabolism and endocrine development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral administration of a beta2-agonist (oral formoterol tablet 160 mg daily for 1 week)</interventions>
    <comparator>Changes in metabolism are compared before and after treatment in the same subject</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>energy expenditure by calorimetry</outcome>
      <timepoint>baseline and 1 week</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>protein turnover by blood analysis</outcome>
      <timepoint>baseline and 1 week after treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy adults</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Any active medical conditions necessitating medication</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Subjects are screened for eligibility by clinical history, physical examination and laboratory blood tests (full blood count, renal function, liver function). Eligible subjects are invited to participate in the study.</concealment>
    <sequence>Non-randomised</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/08/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Health and Medical Research Council</primarysponsorname>
    <primarysponsoraddress>National Health and Medical Research Council 
National Institute of Clinical Studies 
GPO Box 4530 
Melbourne Vic 3001</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>National Health and Medical Research Council 
National Institute of Clinical Studies 
GPO Box 4530 
Melbourne Vic 3001</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study objective is to investigate the metabolic effects of beta2-agonist in humans, including whole body energy expenditure, fat oxidation, protein synthesis and turnover</summary>
    <trialwebsite>None</trialwebsite>
    <publication>None</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>St Vincent's Hospital
Victoria Street
Darlinghurst
NSW 2010</ethicaddress>
      <ethicapprovaldate>30/06/2009</ethicapprovaldate>
      <hrec>1/09/0060</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul Lee</name>
      <address>Garvan Institute of Medical Research
384 Victoria Street
Darlinghurst 
New South Wales 2010</address>
      <phone>+61 2 9295 8486</phone>
      <fax>+61 2 9295 8481</fax>
      <email>p.lee@garvan.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Paul Lee</name>
      <address>Garvan Institute of Medical Research
384 Victoria Street
Darlinghurst 
New South Wales 2010</address>
      <phone>+61 2 9295 8486</phone>
      <fax>+61 2 9295 8481</fax>
      <email>p.lee@garvan.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Paul Lee</name>
      <address>Garvan Institute of Medical Research
384 Victoria Street
Darlinghurst 
New South Wales 2010</address>
      <phone>+61 2 9295 8486</phone>
      <fax>+61 2 9295 8481</fax>
      <email>p.lee@garvan.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>